Cargando…
Integrative Analyses Reveal the Anticancer Mechanisms and Sensitivity Markers of the Next-Generation Hypomethylating Agent NTX-301
SIMPLE SUMMARY: We thoroughly investigated the experimental and preclinical efficacy of the novel hypomethylating agent (HMA) NTX-301 through comparative analyses with conventional HMAs. By performing multiomics data analyses, we demonstrated the mechanisms of action underlying the anticancer activi...
Autores principales: | Lim, Byungho, Yoo, Dabin, Chun, Younghwa, Go, Areum, Kim, Ji Yeon, Lee, Ha Young, Boohaker, Rebecca J., Cho, Kyung-Jin, Ahn, Sunjoo, Lee, Jin Soo, Jung, DooYoung, Choi, Gildon |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10046470/ https://www.ncbi.nlm.nih.gov/pubmed/36980623 http://dx.doi.org/10.3390/cancers15061737 |
Ejemplares similares
-
The preclinical efficacy of the novel hypomethylating agent NTX-301 as a monotherapy and in combination with venetoclax in acute myeloid leukemia
por: Lim, Byungho, et al.
Publicado: (2022) -
Treating Opioid Dependence With Injectable Extended-Release Naltrexone (XR-NTX): Who Will Respond?
por: Nunes, Edward V., et al.
Publicado: (2015) -
ONECUT2 upregulation is associated with CpG hypomethylation at promoter‐proximal DNA in gastric cancer and triggers ACSL5
por: Seo, Eun‐Hye, et al.
Publicado: (2020) -
Open-label Study of Injectable Extended-release Naltrexone (XR-NTX) in Healthcare Professionals With Opioid Dependence
por: Earley, Paul H., et al.
Publicado: (2017) -
Differentially hypomethylated cell-free DNA and coronary collateral circulation
por: Ahn, Jongseong, et al.
Publicado: (2022)